Table 1

Response rates in phase 3 studies comparing imatinib with nilotinib or dasatinib

DASISION

ENESTnd


Median follow-up (months)

18

NR


Minimum follow-up (months)

16

24


Dasatinib 100 mg QD

Imatinib 400 mg QD

Nilotinib 300 mg BID

Nilotinib 400 mg BID

Imatinib 400 mg QD


(N = 259)

(N = 260)

(N = 282)

(N = 281)

(N = 283)


Confirmed complete cytogenetic response by 18 mo (%)

78

70

NR

NR

NR


Major molecular response at any time (%)

57

41

71

67

44


Complete molecular response at any time (%)

13

7

26

21

10


Overall survival (%)

96.0

97.9

97.4

97.8

96.4


Progression-free survival (%)

94.9

93.7

98

97.7

95.2


Discontinued treatment (%)

19

20

26

22

33


Data are based on the update reported at the 2010 Annual Meeting of the American Society of Hematology in Orlando, FL. NR = not reported

Eiring et al. BMC Medicine 2011 9:99   doi:10.1186/1741-7015-9-99

Open Data